Filing Flows › Stoke Therapeutics (STOK) › Guidance & outlook
Stoke Therapeutics (STOK) guidance and outlook
Stoke Therapeutics' 10-Q filed Nov 3, 2026 makes 33 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 3, 2026
- We do not intend to make any further offers or sales of our common stock pursuant to the Sales Agreement under the 2025 Registration Statement.
- We intend to use the 2026 Registration Statement for any future issuances and sales of common stock.
- We expect to continue to incur net losses for the foreseeable future, and we expect our research and development expenses, sales, general and administrative expenses will continue to increase.
- In particular, we expect our expenses and losses to increase as we continue our development of, and seek regulatory approvals for, our product candidates, and begin to commercialize any approved products.
- We do not expect to generate any revenues from product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our product candidates.
- If we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution.
- As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements.
- If we are unable to raise capital, we will need to delay, reduce or terminate planned activities to reduce costs.
- We will continue our educational efforts at major neurology and epilepsy congresses through the remainder of 2026 and into 2027.
- In October 2026, we announced the completion of a successful meeting with the FDA intended to align on key aspects of the planned submission of an NDA for zorevunersen.
- Following the discussion, we plan to use a multicomponent assessment of four prespecified Vineland-3 subdomains to evaluate changes in cognition and behavior in the Phase 3 EMPEROR study.
- In connection with each target, we agreed to collaborate with Acadia to identify potential treatments for further development and commercialization as licensed products.
Stoke Therapeutics' latest quarter
Stoke Therapeutics, Q3 2026: revenue $11.3M (+6% year over year), operating margin -686.9%, net loss $73.6M, operating cash flow −$62.7M. The chart follows the revenue to costs, profit and cash.
Questions
What does Stoke Therapeutics expect?
We do not intend to make any further offers or sales of our common stock pursuant to the Sales Agreement under the 2025 Registration Statement. We intend to use the 2026 Registration Statement for any future issuances and sales of common stock. We expect to continue to incur net losses for the foreseeable future, and we expect our research and development expenses, sales, general and administrative expenses will continue to increase.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.